A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of IDN-6556 compared to
placebo in patients with diagnosed fat deposits in their liver (not caused by alcohol) and
with abnormal liver tests